Astellas Venture Management

Portfolio Companies 2026 for Astellas Venture Management: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Astellas Venture Management accounts for 13 tracked companies with verified cap-table data, 13 of which disclose round sizes totalling $1.5B. The median disclosed raise is $72M, and the largest is Effector Therapeutics at $325M, ahead of Viamet Pharmaceuticals ($178M) and Casma Therapeutics ($162M).

The names that recur most often on these portfolio cap tables are Astellas Venture Management (13 companies), Novartis Venture Fund (3 companies), MPM Capital (3 companies), DCVC Bio (2 companies), Longwood Fund (2 companies), Alexandria Venture Investments (2 companies). By latest disclosed round, the market skews Series A (7), Series B (3), Series D (1), Grant (1).

Best funded Astellas Venture Management companies

  1. Effector Therapeutics — $325M (latest: Series A)
  2. Viamet Pharmaceuticals — $178M (latest: Series D)
  3. Casma Therapeutics — $162M (latest: Grant)
  4. Sidewinder Therapeutics — $162M (latest: Series B)
  5. Oncorus — $141M (latest: Series B)
  6. Orna Therapeutics — $100M (latest: Series A)
  7. Solu Therapeutics — $72M (latest: Series A)
  8. DEM BioPharma — $70M (latest: Series A)
  9. CODA Biotherapeutics — $63M (latest: Series A)
  10. Redona Therapeutics — $61M (latest: Series Unknown)
  11. Mogrify — $49M (latest: Series A)
  12. Catamaran Bio — $42M (latest: Series A)
  13. NeoPhore — $40M (latest: Series B)

Astellas Venture Management — related firms and companies (56)

Astellas Venture Management alternatives · All research reports